Ketamine, a noncompetitive N-methyl-n-aspartate (NMDA) receptor antagonist, has psychotomimetic activity. NMDA receptor antagonists cause morphological damage in the posterior cingulate cortex, which may be the brain region responsible for their psychotomimetic effects. Benzodiazepines are effective in preventing these effects through y-aminobutyric acid A (GABAA) receptor activation. We investigated the effect of propofol, which has both GABAA receptoractivating and NMDA receptor-suppressing activity, on ketamine-induced c-fos expression in the rat posterior cingulate cortex. Propofol or vehicle was continuously infused IV. Fifteen minutes later, 100 mg/kg ketamine or isotonic sodium chloride solution was injected intraperitoneally. Two hours later, brain sections were prepared, and c-fos expression was detected using immunohistochemical methods. Propofol significantly inhibited ketamine-induced c-fos expression in the posterior cingulate cortex. Propofol itself did not induce c-fos expression in this brain region. We conclude that propofol may be able to inhibit ketamine-induced psychotomimetic activity and neuronal damage. Implications: In the present study, we demonstrated that the clinically relevant dose of propofol significantly inhibited ketamine-induced c-fos expression in the rat posterior cingulate cortex. This finding implies that propofol may inhibit ketamine-induced psychotomimetic activity and neuronal damage.
Ketamine, a noncompetitive N-methyl-n-aspartate (NMDA) receptor antagonist, has psychotomimetic activity. NMDA receptor antagonists cause morphological damage in the posterior cingulate cortex, which may be the brain region responsible for their psychotomimetic effects. Benzodiazepines are effective in preventing these effects through y-aminobutyric acid A (GABAA) receptor activation. We investigated the effect of propofol, which has both GABAA receptoractivating and NMDA receptor-suppressing activity, on ketamine-induced c-fos expression in the rat posterior cingulate cortex. Propofol or vehicle was continuously infused IV. Fifteen minutes later, 100 mg/kg ketamine or isotonic sodium chloride solution was injected intraperitoneally. Two hours later, brain sections were prepared, and c-fos expression was detected using immunohistochemical methods. Propofol significantly inhibited ketamine-induced c-fos expression in the posterior cingulate cortex. Propofol itself did not induce c-fos expression in this brain region. We conclude that propofol may be able to inhibit ketamine-induced psychotomimetic activity and neuronal damage. Implications: In the present study, we demonstrated that the clinically relevant dose of propofol significantly inhibited ketamine-induced c-fos expression in the rat posterior cingulate cortex. This finding implies that propofol may inhibit ketamine-induced psychotomimetic activity and neuronal damage. (Anesth Analg 1998; 87:1416-20) K etamine, a noncompetitive N-methyl-Daspartate (NMDA) receptor antagonist, induces undesirable psychological reactions, such as vivid dreams and hallucinations (1). Benzodiazepine administration attenuates such ketamine-induced psychotomimetic activity (2). Noncompetitive NMDA receptor antagonists, such as phencyclidine (PCP), ketamine, and MK801, have produced morphological damage in the posterior cingulate and retrosplenial cortices, which was prevented by either anticholinergic drugs through blockade of the muscarinic Ml receptor or diazepam and barbiturates through activation of the y-aminobutyric acid A (GABAA) receptor (3). The posterior cingulate and retrosplenial cortices may be responsible for the PCP-and ketamineinduced psychotomimetic effects (3,4) also related to schizophrenia (5).
Yet, we demonstrated that ketamine induces c-fos, the protein resulting from activation of the protooncogene c-fos, in various brain areas, such as the cerebral cortices (especially the posterior cingulate cortex) and the thalamic nuclei, but not in the hippocampus (6). Halothane and diazepam significantly inhibited ketamine-induced c-fos expression in the posterior cingulate cortex (7). Because the retrosplenial cortex is often called the posterior cingulate (8), we included it into the posterior cingulate. c-fos expression is widely used as a high-resolution metabolic marker (9) and can be used as a neuroanatomical tracer of noxious stimulation (10) and emotional (11, 12) and behavioral changes (12-14).
Propofol has GABAA receptor-activating (15) and NMDA receptor-inhibiting properties (16). Hallucinations (17), sexual fantasies, and opisthotonos (18) have been reported after propofol administration. Therefore, we sought to determine whether propofol inhibits or aggravates NMDA receptor antagonist-induced psychological and neurological side effects.
The purpose of the present study was to assess the interaction of propofol with ketamine by determining c-fos expression in the posterior cingulate cortex as a 01998 by the International Anesthesia Research Society 0003-2999/98/$5.00 possible representation of the psychotomimetic action and neuronal injury of ketamine.
Methods
The study was approved by our animal research committee. All experiments were performed on male Wistar rats weighing 280-380 g. Twenty rats were assigned to four groups. In Group 1 (n = 5), rats were first anesthetized with 3% sevoflurane in 60% N,O and 40% Oz. The right femoral artery was cannulated for the measurement of arterial blood pressure and sampling of blood for gas analysis. The tail vein was cannulated for the administration of fluids and drugs. Tracheotomy was performed, and mechanical ventilation was instituted using an animal respirator with the aid of pancuronium. End-tidal CO, was maintained at 30-35 mm Hg throughout the experiment. Sevoflurane was stopped, and 20 pg/kg fentanyl was administered. Thirty minutes after the cessation of sevoflurane, the rats received an IV bolus of 2 mg/kg propofol followed by continuous infusion at 10 mg * kg-r * h-i unt i 1 b rain fixation. Fifteen minutes after the beginning of propofol infusion, 100 mg/kg ketamine was injected intraperitoneally. In Group 2 (n = 5), the experimental conditions were the same as for Group 1, but 5 mg + kg-l * h-l propofol was infused continuously without a bolus injection. In Group 3 (In-tralipid@ group) (n = 5), the experimental conditions were the same as for Group 1, but instead of propofol, Intralipid@ (Pharmacia AB, Stockholm, Sweden) was continuously infused at the same infusion rate as propofol. In Group 4 (isotonic sodium chloride solution group) (n = 5), the experimental conditions were the same as for Group 1, but instead of ketamine, the same volume of isotonic sodium chloride solution was injected intraperitoneally.
For the propofol experiments, propofol in its clinical formulation (Diprivan@; Zeneca Pharmaceuticals, Wilmington, DE) was used and diluted with Intralipid@ to the appropriate volume of infusion. The mean arterial blood pressure was maintained >80 mm Hg with a drip infusion of phenylephrine. The sevoflurane concentration was continuously monitored using an Anesthetic Gas Monitor (Briiel & Kjaer, Naerum, Denmark). A rectal thermometer was inserted, and the temperature was maintained at 37"C-38°C using a warm waker mattress and a heating lamp.
Two hours later, the rats were deeply anesthetized with sevoflurane. They were perfused transcardially, initially with ice-cold 0.01 M phosphate-buffered saline (0.01 M PBS; 0.9% NaCl in 0.01 M phosphate buffer, pH 7.4), then with a fixative solution containing 4% paraformaldehyde, 0.2% picric acid, and 0.35% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4 (0.1 M PB). The brain was quickly removed from the skull and immersed for 1 day in a postfixative solution containing 4% paraformaldehyde and 0.2% picric acid in O.lM PB at 4°C. The brain was then placed in 0.1 M PB containing 15% sucrose and 0.1% sodium azide at least until it sank. The brain was frozen and cut into 20-pm coronal sections in a cryostat. The sections were immersed in 0.1 M PBS at 4°C. A total of 30 coronal sections per animal were made at the plane of approximately interaural 6.2 mm (19) . From these sections, three sections were selected at intervals of five sections and subjected to the immunohistochemical procedure.
Unless otherwise stated, all incubations were performed at room temperature. The sections were incubated with a polyclonal anti-c-fos antibody (Oncogene Science, Inc., Uniondale, NY) at a dilution of 1:lOOO in 0.1 M PBST (0.1 M PBS containing 0.3% Triton X-100) at 4°C for 4 days. The sections were washed three times with 0.1 M PBST, 10 min per wash, and incubated with biotinylated anti-rabbit antibody (1:lOOO dilution in 0.1 M PBST; Vector Laboratories, Burlingame, CA) for 1.5 h. After washing, the sections were incubated with an avidin-biotin-peroxidase complex (1:800 dilution in 0.1 M PBST; Vector Laboratories) as described by Hsu et al. (20) for 1.5 h. The sections were then reacted with a solution containing 0.0045% H,O,, 0.02% 3,3'diaminobenzidine 4 HCl, and 0.3% nickel ammonium sulfate in 0.05 M Tris-HCl, pH 7.6, for 5 min. Immunohistochemically detected nuclear-associated reaction product was referred to Fos-like immunoreactivity (Fos-LI). To confirm the specificity of immunostaining, some sections were incubated with anti-c-fos antibody preabsorbed with an excess of the peptide against which the antibody was raised and confirmed to yield no cellularspecific reaction product.
Quantification of c-fos expression was performed with respect to the number of Fos-LI-positive boutons in approximately the same brain region per section using a computer-assisted image analyzer attached to a light microscope (x40 magnification) and a highresolution color video camera, as described previously (8). The images of purple-blue stained Fos-LI-positive boutons were transferred to a color monitor screen through the light microscope. An analysis field (0.894 mm2) was fixed on the screen. The image was digitized semiautomatically, depending on the intensity of positive color-staining, by gray brightness level ranging from 0 to 256. An appropriate gray level threshold was chosen to selectively label the positive boutons. The threshold was usually set on the lightest stained nucleus in each section. "Ignored minimum area" of the positive staining was first set to exclude staining of dust (in the present study, 2 pm2). Minor errors such as pseudopositive dots, which were apparently not nuclei (i.e., those that were irregular in shape, those that were too large in size, and overlapping boutons) were all manually corrected by using the erasing function of the analyzer. NAGATA ET -FOS 1998; 87:1416-20 Physiological data were analyzed by using one-way analysis of variance. Post hoc differences among groups were identified by using Bonferroni's test. We counted the Fos-LI-positive boutons of three sections per animal, the mean of which represented the number for each individual animal. The number of Fos-LIpositive boutons of each group is expressed as mean -C SEM (n = 5 in each group). Statistical comparisons among groups were performed by using analysis of variance, followed by Bonferroni adjustment of the t-test independently. P < 0.05 was considered statistically significant.
Results
Mean arterial pressure (MAP) was significantly higher in Group 4 compared with that in other groups (Table I) . We used phenylephrine for two of five rats only in Group 1 to maintain MAP >80 mm Hg after the ketamine injection.
Propofol reduced the ketamine-induced Fos-LI in the posterior cingulate cortex in a dose-dependent manner (Fig. 1) . The number of Fos-LI-positive boutons in the posterior cingulate cortex of rats in Group 3 was 130.8 + 14.3, which was reduced by a continuous infusion with propofol at 5 mg * kg-l * h-l (Group 2) and by a 2-mg/kg bolus injection followed by continuous infusion at 10 mg * kg-l . h-l (Group 1) to 23.6 2 5.6 and 4.0 +-2.9, respectively (P < 0.001) (Fig. 2) . Propofol itself did not induce Fos-LI in the posterior cingulate cortex (Group 4).
Discussion
In the present study, we demonstrated that propofol inhibited ketamine-induced c-fos expression in the rat posterior cingulate cortex and that propofol itself did not induce it.
In the present study, the brain was fixed 2 h after the administration of ketamine, which is the time required for maximal Fos-LI expression after ketamine administration (6). The dose of ketamine, 100 "g/kg, was supraclinical, and the groups that received ketamine had lower MAP values than Group 4, to which ketamine was not administered. However, we chose this dose because we previously showed that it induced the most marked c-fos expression (6). The reduction in MAP induced by ketamine did not affect the c-fos expression because Groups l-3 did not show a significant difference in MAP. Olney et al. (3, 4) demonstrated that NMDA receptor antagonists such as PCP, ketamine, and MK801 induced neuronal vacuole formation in the posterior cingulate cortex, and that muscarinic Ml antagonists or diazepam and barbiturates blocked this neuronal damage. Sharp et al. (21) demonstrated that haloperidol, a dopamine and a-receptor blocker, also prevented the induction of HSP70 induced by noncompetitive NMDA receptor antagonists in the posterior cingulate cortex. Olney et al. (3, 4) and Sharp et al. (21) also suggested that the posterior cingulate cortex is the brain region responsible for NMDA receptor antagonist-induced psychotomimetic activities and for schizophrenia. Lahti et al. (5) reported that, when given to schizophrenic individuals in subanesthetic doses, ketamine produced an activation of their psychotic symptoms that was similar to those of their usual psychotic episodes. c-fos is usually expressed rapidly and transiently in response to a variety of extracellular stimuli (lo-12,22) . It acts as a third messenger molecule in signal transduction systems, in which it couples short-term signals elicited by cell surface stimulation to long-term adaptive modifications by regulating the pattern of gene expression (23,24). c-fos expression can be used as an indicator of plastic changes in regional brain functions (23,24), cell excitation (9), and the process of cell damage (22) . Gass et al. (25) demonstrated that MK801 caused immediate early gene expression, including c-fos, in the posterior cingulate cortex and suggested that it might be a rapid and sensitive indicator of nonlethal neuronal injury. However, Nakki et al. (26) reported that c-fos expression induced by PCP in the posterior cingulate cortex was prolonged and could reflect cell injury and death. In a pilot study, however, we found that the dose of ketamine we used in the present study did not cause the disruption of microtubule-associated protein 2, Figure  1 . Fos-like immunoreactivity in the rat posterior cingulate cortex 2 h after the intraperitoneal administration of 100 mg/kg ketamine.
A, IV injection of 2 mg/kg propofol followed by continuous infusion at 10 mg * kg-i * h-i started 15 min before the ketamine injection (Group 1 suggested that PCP-induced c-fos expression may underlie the behavioral and/or psychotomimetic effects of PCP. Heilig et al. (13) and Hooper et al. (14) demonstrated that manipulating cocaine-or n-amphetamine induced c-fos expression by the direct infusion of antisense oligonucleotides in specific brain regions could have behavioral consequences and suggested that c-fos expression may play a role in the functional output. Thus, the marked expression of Fos-LI induced by ketamine in the posterior cingulate cortex reflects neuronal activation and suggests functional changes, such as psychotomimetic activity that may originate from the brain region, and neuronal damage in this brain region.
The prevention of ketamine-induced c-fos expression in the posterior cingulate cortex by propofol suggests that propofol may suppress these activities induced by ketamine. Contrary to our expectations, very small doses of propofol for rats (28) receptor antagonist, in the rat posterior cingulate/retrosplenial cortices, which supports our findings. However, they studied histology instead of c-fos, and they used MK801 instead of ketamine. Furthermore, they neither monitored nor recorded hemodynamic and respiratory variables.
Propofol has GABAA receptor-activating (15) and NMDA receptor-antagonist (16) properties. The failure of propofol itself to induce Fos-LI expression in the posterior cingulate cortex suggests that, even if propofol has hallucinogenic properties, the mechanism in such cases may be different from that of NMDA receptor antagonists. This study also suggests ET AL. PROPOFOL, KETAMINE, AND C-FOS ANALG 1998; 87:1416-20 that the combined use of ketamine and propofol may be beneficial for brain protection. Although ketamine is a clinically available NMDA receptor antagonist, it has not been widely used as a neuroprotective drug because of its adverse effects. Propofol, which has a short duration of action, allows a rapid recovery, and has a potential for brain protection because of its antioxidant (30) and GABAA receptor-activating (15) properties, may be able to inhibit NMDA receptor antagonists' adverse effects. In conclusion, the results of the present study in experimental animals show that a clinically relevant dose of propofol suppresses the effects of ketamine on the posterior cingulate cortex, which is extremely sensitive to NMDA receptor antagonists, and may be the area of the brain concerned with the psychotomimetic action and neuronal damage of NMDA receptor antagonists.
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